메뉴 건너뛰기
European Journal of Cancer
Volumn 50, Issue 10, 2014, Pages 1717-1721
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme

(19)  Khan, F a   Ottensmeier, C b   Popat, S c   Dua, D d   Dorey, N e   Ellis, S f   Szabo, M b   Upadhyay, S g   Califano, R h   Chan, S i   Lee, L h   Ali, C W j   Nicolson, M k   Bates, A T b   Button, M l   Chaudhuri, A m   Mulvenna, P n   Shaw, H M o   Danson, S J a  

Author keywords

Afatinib; EGFR; Non small cell lung cancer
Indexed keywords

AFATINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; PLATINUM;
EID: 84901761113     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.001     Document Type: Article
Times cited : (12)
References (13)
  • 1
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 2
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • F.A. Shepherd, J.R. Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 3
    • 57149089886 scopus 로고    scopus 로고
    • EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan
    • T. Takano, T. Fukui, and Y. Ohe et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan J Clin Oncol 26 2008 5589 5595
    • (2008) J Clin Oncol , vol.26 , pp. 5589-5595
    • Takano, T.1    Fukui, T.2    Ohe, Y.3
  • 4
    • 17844390172 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
    • W. Pao, and V.A. Miller Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions J Clin Oncol 23 2005 2556 2568
    • (2005) J Clin Oncol , vol.23 , pp. 2556-2568
    • Pao, W.1    Miller, V.A.2
  • 5
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
    • C. Zhou, Y.L. Wu, and G. Chen et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 6
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 7
    • 47949114668 scopus 로고    scopus 로고
    • Detection of mutations in EGFR in circulating lung-cancer cells
    • S. Maheswaran, L.V. Sequist, and S. Nagrath et al. Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
    • (2008) N Engl J Med , vol.359 , pp. 366-377
    • Maheswaran, S.1    Sequist, L.V.2    Nagrath, S.3
  • 8
    • 84863011443 scopus 로고    scopus 로고
    • Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer
    • K.Y. Su, H.Y. Chen, and K.C. Li et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 30 2012 433 440
    • (2012) J Clin Oncol , vol.30 , pp. 433-440
    • Su, K.Y.1    Chen, H.Y.2    Li, K.C.3
  • 9
    • 38049038935 scopus 로고    scopus 로고
    • A phase i dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    • F.A. Eskens, C.H. Mom, and A.S. Planting et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br J Cancer 98 2008 80 85
    • (2008) Br J Cancer , vol.98 , pp. 80-85
    • Eskens, F.A.1    Mom, C.H.2    Planting, A.S.3
  • 10
    • 49149118719 scopus 로고    scopus 로고
    • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    • D. Li, L. Ambrogio, and T. Shimamura et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
    • (2008) Oncogene , vol.27 , pp. 4702-4711
    • Li, D.1    Ambrogio, L.2    Shimamura, T.3
  • 11
    • 77957585027 scopus 로고    scopus 로고
    • Phase i trial of the irreversible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumours
    • T.A. Yap, L. Vidal, and J. Adam et al. Phase I trial of the irreversible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumours J Clin Oncol 28 2010 3965 3972
    • (2010) J Clin Oncol , vol.28 , pp. 3965-3972
    • Yap, T.A.1    Vidal, L.2    Adam, J.3
  • 12
    • 84862785051 scopus 로고    scopus 로고
    • Afatanib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
    • V.A. Miller, V. Hirsh, and J. Cadranel et al. Afatanib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 2012 528 538
    • (2012) Lancet Oncol , vol.13 , pp. 528-538
    • Miller, V.A.1    Hirsh, V.2    Cadranel, J.3
  • 13
    • 84873814691 scopus 로고    scopus 로고
    • Symptom and quality of life benefit of afatanib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase IIb/III trial (LUX-Lung 1)
    • V. Hirsch, J. Cadranel, and X.J. Cong et al. Symptom and quality of life benefit of afatanib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1) J Thorac Oncol 8 2013 229 237
    • (2013) J Thorac Oncol , vol.8 , pp. 229-237
    • Hirsch, V.1    Cadranel, J.2    Cong, X.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.